8.10
+0.04(+0.50%)
Currency In USD
Previous Close | 8.06 |
Open | 7.85 |
Day High | 8.35 |
Day Low | 7.7 |
52-Week High | 15.1 |
52-Week Low | 1.42 |
Volume | 1.26M |
Average Volume | 1.53M |
Market Cap | 438.89M |
PE | -2.07 |
EPS | -3.91 |
Moving Average 50 Days | 9.28 |
Moving Average 200 Days | 7.1 |
Change | 0.04 |
If you invested $1000 in Emergent BioSolutions Inc. (EBS) 10 years ago, it would be worth $301.9 as of December 21, 2024 at a share price of $8.1. Whereas If you bought $1000 worth of Emergent BioSolutions Inc. (EBS) shares 5 years ago, it would be worth $147.38 as of December 21, 2024 at a share price of $8.1.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
GlobeNewswire Inc.
Dec 16, 2024 1:00 PM GMT
GAITHERSBURG, Md., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the Biomedical Advanced Research and Development Authority (BARDA) within the Administration for Strategic Preparedness and Response (A
Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa
GlobeNewswire Inc.
Nov 06, 2024 9:49 PM GMT
PANTHER to conduct clinical trial under the leadership of Africa Centres for Disease Control and Prevention GAITHERSBURG, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that brincidofovir (brand name T
Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development
GlobeNewswire Inc.
Nov 04, 2024 12:30 PM GMT
Executive Management Team appointments contribute to Emergent’s transformation and beyond, including promotion of Jessica Perl to General Counsel and Corporate Secretary GAITHERSBURG, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc